Home  > News  > Noteworthy


Please find below news in brief from Ascenion, its partners and the technology transfer sector:


Successful Phase I study of Berlin Cures‘ novel treatment against heart failure

Berlin Cures, one of Ascenion’s portfolio companies, has announced positive Phase I results for its lead candidate BC007 for the treatment of heart failure. 68 subjects were evaluated in the clinical study. The candidate was very well tolerated and a single dose was able to completely and sustainably eliminate autoantibodies targeting the beta-1 adrenoceptor. These autoantibodies are present in the majority of heart failure patients and play a crucial role in the development of the disease.

The results confirm the potential of Berlin Cures’ innovative therapeutic concept, which represents the first causal treatment approach to heart failure. The specific elimination of autoantibodies could provide a compelling alternative to expensive and stressful dialysis or cardiac assist devices.

Berlin Cures plans to start a Phase II clinical study of BC007 in the second quarter of 2018.

Further information: Berlin Cures’ press release


11th BioVaria on April 23-24, 2018: Strong line-up of technologies

BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international biopharmaceutical industry. Top-tier academic institutions and universities from all over Europe will present over 60 attractive partnering and investment opportunities in the life-science field.

  • Unparalleled density of highly innovative commercial opportunities
  • Topics cover research tools, potential diagnostics and therapeutics in major disease areas
  • 17 technology transfer partners from seven European countries representing about 50 institutions
  • 10 life-science startups from Germany, Czech Republic and the UK participating in this year’s Startup Pitch and Partner event
  • Interactive panel discussion to explore the topic of ‘successful drug development for rare diseases’ moderated by Prof. Horst Domdey (BioM) with expert speakers from Canada, Germany and the Netherlands

Register here www.biovaria.org.

Further information:

Technologies online



Charité BIH Entrepreneurship Summit, Berlin, May 7-8, 2018

Join over 400 experts in medical innovation to discuss global challenges and pioneering technologies in healthcare. During two conference days, you will get access to entrepreneurs, scientists and clinicians, policymakers, investors, and industry leaders.

Our agenda features inspiring keynote speakers from Germany, Europe, Israel, Canada, the United States, and our partner country Australia. Broad-ranging panel discussions on Artificial Intelligence, Blockchain in Healthcare, and Affordability of Medication will provide insights into emerging markets and trends.

Interactive workshops and the Life Sciences Venture Market offer opportunities for entrepreneurs to learn about relevant strategic issues and to present their companies to international investors.

Ascenion is partner of the Charité Entrepreneurship Summit 2018. As member of our network you can save up to 33%. Please contact us!

Find out more about the Summit and register at www.charite-summit.de


Startup Pitch & Partner Application Deadline: 16 February 2018

Don’t miss your chance to secure a spot at BioVaria on 23./24. April 2018 to pitch your company to leading investors and biopharmaceutical decision makers, get invaluable guidance from industry experts in dedicated 1:1 meetings and network with fellow entrepreneurs, including startup keynote speaker Dr. Hella Kohlhof, CSO, Immunic Therapeutics.

European life-science spin-offs and startups can apply online at www.biovaria.org

Learn more!


TechnologieAllianz Annual Conference on 12 April 2018 in Frankfurt

The 3rd TechnologieAllianz Annual Conference will focus on science start-ups and their importance for the future of the German economy. Prominent speakers will explain how knowledge and technology transfer can help entrepreneurs, and introduce the available funding instruments. Further contributions will come from technology transfer experts, company founders, investors and stakeholders representing various sectors.

Register now!

More information


Networked TT: Intensive workshop for Ascenion’s partners

Eye-to-eye networking, acquiring deeper knowledge, sharing experiences, keeping informed about new developments – these are the aims of the TT workshop organized each year by Ascenion exclusively for its partner institutes. This year, 10 participants responsible for technology transfer at various research institutes und universities in Germany and Austria gathered in Munich.

The programme included information on the TT-relevant consequences of Brexit, as well as hands-on tips for drawing up term sheets, negotiating with partners in Asia and acquiring support for start-ups. ‘This is the first time we’ve attended the workshop, and we are extremely impressed by its practical relevance,’ said Dr Peter Josten, Head of the Service Center Research from the Medical University of Innsbruck. ‘Start-ups in particular play an important role for us at present.’ Many participants also appreciated the opportunity for intensive discussions made possible by the small scale of the workshop and the cooperative atmosphere.

We invite all Ascenion’s partners to submit their requests and suggestions for the next workshop in January 2019.


Biotech NetWorkshop – Where founders, experts and investors meet

Biotech NetWorkshop, organized by Ascenion and Max Planck Innovation, offers the opportunity for scientists interested in founding new start-ups to network with experienced founders of more mature life science companies from the Max Planck Society, the Helmholtz Association, the Leibniz Association and the Hanover Medical School.

We are looking forward to a diverse lecture programme with talks on "Financing trends", "Business models and market entry strategies" and "Bridging the gap concepts”. In a panel discussion moderated by Prof. Dr. Horst Domdey, we will focus on two topics "Trends, perspectives and challenges of the Biotech Industry" and later "Digital health". In addition, we will be joined by well-known experts from industry and finance, who will give lectures and discuss these topics. Another highlight will be the presentation from rally driver Jutta Kleinschmidt, one of the most, if not the most successful woman in global motorsport. Jutta will discuss the topic "Challenges" against the background of her athletic career.

For further information:

Full programme

Register now!


Merry Christmas!

Dear Partners and Clients,

We thank you for the enjoyable teamwork over the past year, and wish you and your families a merry Christmas and all the best for 2018.

Instead of sending Christmas cards this year, we have decided to make a donation to the charitable association "Eat to fight your disease e. V.". The project supports patients of the Centre Hospitalier Universitaire Butare (CHUB) in Huye, Rwanda.

You can find more information on the project here: www.etfyd.eu.

Your Ascenion Team


Save the date: Next BioVaria on 23-24 April 2018, Munich

BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international biopharmaceutical industry.
Top-tier academic institutions and universities from all over Europe will present over 60 attractive partnering and investment opportunities in the life-science field – each one selected for BioVaria in a peer-review process.

2018 will feature a new and expanded program for startups. Selected emerging and rising startups will have the chance to pitch their companies to potential investors. Moreover, the startup teams will receive valuable advice from experienced investors and industry experts, both through the startup-focused keynote and one-on-one mentoring discussions.

The technology presentations at the partner booths - and last but not least the networking evening at the Augustiner-Keller - offer ample opportunity to deepen discussions and initiate collaborations.

The conference is organised by Ascenion and several other technology transfer organisations from all across Europe.

Don’t miss BioVaria 2018! Register now at www.biovaria.org


Welcome to the team!

Dr Ansgar Santel joined our Berlin office as Technology Development Manager in November 2017. He brings 15 years’ experience in the international biotech industry to the team, and in particular his expertise and enthusiasm for the translational development of innovative therapies. As Senior Scientist Translational & Clinical Research in a German-English biotech company, he advanced a novel RNAi-therapy from its conception through to clinical testing. A further focus of his work was the initiation and management of research alliances between industry and academia. Together with his colleagues at Ascenion, he will use this experience to effectively support scientists at Ascenion’s partner institutes during the application-oriented development of their research projects.

Ansgar studied biology at the Phillips-Universität, Marburg, Germany, where he also gained a PhD in molecular biology, before spending four years as a postdoctoral fellow at the Stanford University School of Medicine, Palo Alto, USA.


Figures and highlights 2016: Ascenion’s Annual Report

In this year's report we are pleased to present figures and highlights for 2016 together with selected project examples.

Based on research at our partner institutes, two products received market approval and three clinical trials started in 2016. In addition, Cardior Pharmaceuticals GmbH was founded and six portfolio companies received new or extended financing, including EUR 9 million Series A financing for HepaRegenix last December.

The project pipeline is well filled: last year we intensively supported six further start-ups and several technology developments, examined around 100 new invention disclosures and concluded over 100 agreements, 39 of which revenue-generating.

Our partners’ revenues in 2016 from licence, option and material transfer agreements negotiated by us totalled over EUR 11 million. Furthermore, Ascenion distributed EUR 1 million to the LifeScience Foundation, most of which was made available as funding for research projects at the Foundation’s endowing institutes.

We are particularly delighted that two further partner institutes chose to become endowing institutes of the LifeScience Foundation last year: Charité – Universitätsmedizin Berlin and the Research Center Borstel (FZB), an institute of the Leibniz Association.

Our thanks go to all endowing and partner institutes, whose research activities and trust in our team form the basis for successful technology transfer.

Download Ascenion Annual Report 2016


Ascenion’s portfolio company OMEICOS extends Series B financing to address new indications

OMEICOS Therapeutics, a spin-off from the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), announced the second closing of its Series B financing round with US-based REMIGES Ventures. The financing enables OMEICOS to establish a US-based subsidiary in Cambridge Massachusetts and to expand its technology into the field of eye diseases. The company plans to evaluate a range of compounds and different routes of administration for different types of eye diseases.

In the first quarter of 2017, OMEICOS reported the first closing of a Series B financing and initiated a Phase I trial with its lead compound OMT-28. So far, clinical development has focused on cardiovascular diseases, namely atrial fibrillation, the most common cardiac arrhythmia in humans.

For further information see:

OMEICOS press release


In cooperation with TechnologieAllianz: Ascenion offers training courses

TechnologieAllianz is the German association for knowledge and technology transfer (KTT) and brings together universities, national research institutions and transfer service providers in a nationwide network. TechnologieAllianz is promoting the development and recognition of the KTT profession in Germany and is also striving towards sharing best practice among their members as well as with other international KTT institutions and networks worldwide. Additionally, TechnologieAllianz organises KTT training, workshops and conferences.

As a member of TechnologieAllianz, Ascenion will conduct two further-education training courses on the topic of equity management and one on contracts for research projects. 

Learn more


Join BioFIT 2017, Europe’s Top Event for Public and Private Life-Science Collaborations

As a supporter of BioFIT Ascenion cordially invites all its partners to join this partnering event for open innovation, technology transfer and collaborative research in the life sciences, to take place on 28-29 November 2017 in Strasbourg, France.

BioFit brings together over 1,200 international leading stakeholders in the sector offering and seeking opportunities to

  • initiate new partnerships,
  • foster the emergence of collaborative projects, and
  • intensify the flow of licenses in the field of life sciences.

Further information:

Learn more!
Preliminary agenda


BioEntrepreneurship Summit October 10-11, 2017, Munich

Get your earlybird ticket now!

Launching a life science or health tech venture is among the most complex and risky entrepreneurial undertaking, given extremely long development cycles, a strictly regulated approval process, high levels of technological and market uncertainty, and often extraordinary capital requirements. Technology convergence and the transformation of healthcare towards digital and personalized medicine enables entirely new products and services and paves the way for new business models but also poses a challenge for future or actual founders. BioEntrepreneurs largely profit from sector-specific support and specialized training and acceleration. They need to have access to experience in a multitude of disciplines as well as an extensive network to build sustainable ventures.

The BioEntrepreneurship Summit aims to bring together all relevant stakeholders of the bioentrepreneurial and health tech ecosystem.

Ascenion is partner of the BioEntrepreneurship Summit 2017. Get your earlybird ticket now at www.bioentrepeneurshipsummit.org